ArticleReproductive medicine and biology
Can Omegaven Avoid the Destructive Effect of Procarbazine Over Ovarian Reserve?
Article in Reproductive medicine and biology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Procarbazine, an alkylating agent, depletes ovarian reserve. Omegaven exhibits anti-apoptotic, anti-inflammatory, and antioxidant properties. We aimed to investigate the preventative benefits of Omegaven against the deleterious effects of Procarbazine on the ovaries. Methods: Thirty female rats were categorized into groups: Control, Results: Total follicle count calculated from evaluated sections is significantly reduced in the Procarbazine group compared to other groups. Immunoreactivities of inflammatory and apoptotic markers were significantly elevated in the Procarbazine group and were diminished significantly in the Procarbazine+Omegaven group. In the Procarbazine group, ultrastructural alterations due to atresia were marked by the presence of lipid droplets, multivesicular bodies, and eosinophil infiltration. The ultrastructural alterations were less pronounced in the Procarbazine + Omegaven group. In the Procarbazine group, prooxidative, inflammatory, and apoptotic markers in ovarian tissue were elevated, while antioxidative indicators were significantly diminished. Blood chemistry analyses yielded comparable results. AMH levels were markedly reduced in the Procarbazine Group compared to the control group. The AMH levels in the Procarbazine + Omegaven group exhibit a rise significantly in blood serum samples. Conclusions: Omegaven is a promising pharmacological agent for mitigating the deleterious effects of Procarbazine on ovarian reserve.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.